eyesplash/Flickr

Contributing correspondent Kai Kupferschmidt talks with host Sarah Crespi about the success of a fast moving megatrial for coronavirus treatments. The United Kingdom’s Recovery (Randomized Evaluation of COVID-19 Therapy) trial has enrolled more than 12,000 hospitalized coronavirus patients since early March and has released important recommendations that were quickly taken up by doctors and scientists around the world. Kupferschmidt discusses why such a large study is necessary and why other large drug trials like the World Health Organization’s Solidarity trial are lagging behind.

Read Science’s coronavirus coverage.

Also this week, producer Meagan Cantwell talks with Saul Villeda